CATALYST PHARMACEUTICALS INC (CPRX) Fundamental Analysis & Valuation

NASDAQ:CPRX • US14888U1016

24.09 USD
-0.23 (-0.95%)
Last: Mar 6, 2026, 11:37 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

CPRX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPRX is growing strongly while it also seems undervalued. This is an interesting combination This makes CPRX very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. CPRX Profitability Analysis

1.1 Basic Checks

  • In the past year CPRX was profitable.
  • In the past year CPRX had a positive cash flow from operations.
  • CPRX had positive earnings in each of the past 5 years.
  • In the past 5 years CPRX always reported a positive cash flow from operatings.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

1.2 Ratios

  • CPRX has a better Return On Assets (19.41%) than 96.73% of its industry peers.
  • With an excellent Return On Equity value of 22.46%, CPRX belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
  • CPRX has a better Return On Invested Capital (20.39%) than 97.88% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CPRX is in line with the industry average of 19.05%.
  • The 3 year average ROIC (19.09%) for CPRX is below the current ROIC(20.39%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 19.41%
ROE 22.46%
ROIC 20.39%
ROA(3y)17.95%
ROA(5y)18.52%
ROE(3y)21.13%
ROE(5y)22.03%
ROIC(3y)19.09%
ROIC(5y)20.07%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • CPRX has a better Profit Margin (36.39%) than 96.92% of its industry peers.
  • In the last couple of years the Profit Margin of CPRX has declined.
  • CPRX has a Operating Margin of 43.77%. This is amongst the best in the industry. CPRX outperforms 99.23% of its industry peers.
  • CPRX's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 85.19%, CPRX belongs to the top of the industry, outperforming 87.69% of the companies in the same industry.
  • CPRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 43.77%
PM (TTM) 36.39%
GM 85.19%
OM growth 3Y-2.71%
OM growth 5Y4.77%
PM growth 3Y-2.11%
PM growth 5Y-10.39%
GM growth 3Y0.49%
GM growth 5Y-0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CPRX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
  • Compared to 1 year ago, CPRX has more shares outstanding
  • The number of shares outstanding for CPRX has been increased compared to 5 years ago.
  • There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • CPRX has an Altman-Z score of 14.62. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 14.62, CPRX belongs to the top of the industry, outperforming 86.73% of the companies in the same industry.
  • CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 14.62
ROIC/WACC2.34
WACC8.73%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • CPRX has a Current Ratio of 6.08. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 6.08, CPRX is in the better half of the industry, outperforming 63.27% of the companies in the same industry.
  • A Quick Ratio of 5.82 indicates that CPRX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.82, CPRX is in the better half of the industry, outperforming 62.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.08
Quick Ratio 5.82
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. CPRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.01% over the past year.
  • Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 32.75% on average per year.
  • Looking at the last year, CPRX shows a quite strong growth in Revenue. The Revenue has grown by 19.78% in the last year.
  • CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.67% yearly.
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
Revenue 1Y (TTM)19.78%
Revenue growth 3Y40.1%
Revenue growth 5Y37.67%
Sales Q2Q%7.61%

3.2 Future

  • CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.46% yearly.
  • The Revenue is expected to grow by 9.11% on average over the next years. This is quite good.
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

7

4. CPRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 14.25, which indicates a correct valuation of CPRX.
  • 95.58% of the companies in the same industry are more expensive than CPRX, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.69. CPRX is valued slightly cheaper when compared to this.
  • CPRX is valuated correctly with a Price/Forward Earnings ratio of 12.47.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.92% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.79, CPRX is valued a bit cheaper.
Industry RankSector Rank
PE 14.25
Fwd PE 12.47
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaper than 97.69% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.73% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.1
EV/EBITDA 7.65
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of CPRX may justify a higher PE ratio.
PEG (NY)1
PEG (5Y)0.44
EPS Next 2Y13.06%
EPS Next 3Y6.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPRX Dividend Analysis

5.1 Amount

  • No dividends for CPRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPRX Fundamentals: All Metrics, Ratios and Statistics

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (3/6/2026, 11:37:32 AM)

24.09

-0.23 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners86.97%
Inst Owner Change-0.4%
Ins Owners5.48%
Ins Owner Change1.13%
Market Cap2.94B
Revenue(TTM)588.99M
Net Income(TTM)214.33M
Analysts88.57
Price Target35.19 (46.08%)
Short Float %8.4%
Short Ratio7.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.83%
Min EPS beat(2)19.63%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)19.39%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)17.18%
EPS beat(12)10
Avg EPS beat(12)14.79%
EPS beat(16)13
Avg EPS beat(16)11.51%
Revenue beat(2)2
Avg Revenue beat(2)5.84%
Min Revenue beat(2)5.34%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.83%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.89%
Revenue beat(12)11
Avg Revenue beat(12)3.56%
Revenue beat(16)14
Avg Revenue beat(16)3.41%
PT rev (1m)0.21%
PT rev (3m)0%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)15.86%
EPS NY rev (1m)0.19%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.91%
Valuation
Industry RankSector Rank
PE 14.25
Fwd PE 12.47
P/S 4.99
P/FCF 14.1
P/OCF 14.1
P/B 3.08
P/tB 3.58
EV/EBITDA 7.65
EPS(TTM)1.69
EY7.02%
EPS(NY)1.93
Fwd EY8.02%
FCF(TTM)1.71
FCFY7.09%
OCF(TTM)1.71
OCFY7.09%
SpS4.82
BVpS7.81
TBVpS6.74
PEG (NY)1
PEG (5Y)0.44
Graham Number17.24
Profitability
Industry RankSector Rank
ROA 19.41%
ROE 22.46%
ROCE 26.94%
ROIC 20.39%
ROICexc 78.78%
ROICexgc 168.22%
OM 43.77%
PM (TTM) 36.39%
GM 85.19%
FCFM 35.42%
ROA(3y)17.95%
ROA(5y)18.52%
ROE(3y)21.13%
ROE(5y)22.03%
ROIC(3y)19.09%
ROIC(5y)20.07%
ROICexc(3y)57.9%
ROICexc(5y)154.04%
ROICexgc(3y)178.31%
ROICexgc(5y)N/A
ROCE(3y)25.22%
ROCE(5y)26.51%
ROICexgc growth 3YN/A
ROICexgc growth 5Y9.61%
ROICexc growth 3Y-41.48%
ROICexc growth 5Y-5.82%
OM growth 3Y-2.71%
OM growth 5Y4.77%
PM growth 3Y-2.11%
PM growth 5Y-10.39%
GM growth 3Y0.49%
GM growth 5Y-0.11%
F-Score6
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.15%
Cap/Sales 0.01%
Interest Coverage 553.17
Cash Conversion 70.58%
Profit Quality 97.33%
Current Ratio 6.08
Quick Ratio 5.82
Altman-Z 14.62
F-Score6
WACC8.73%
ROIC/WACC2.34
Cap/Depr(3y)0.78%
Cap/Depr(5y)100.47%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)148.03%
Profit Quality(5y)146.81%
High Growth Momentum
Growth
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue 1Y (TTM)19.78%
Revenue growth 3Y40.1%
Revenue growth 5Y37.67%
Sales Q2Q%7.61%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%
EBIT growth 1Y32.11%
EBIT growth 3Y36.3%
EBIT growth 5Y44.23%
EBIT Next Year28.53%
EBIT Next 3Y17.44%
EBIT Next 5YN/A
FCF growth 1Y-12.81%
FCF growth 3Y21.61%
FCF growth 5Y35.9%
OCF growth 1Y-12.98%
OCF growth 3Y21.62%
OCF growth 5Y35.91%

CATALYST PHARMACEUTICALS INC / CPRX FAQ

What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPRX.


What is the valuation status for CPRX stock?

ChartMill assigns a valuation rating of 7 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.


Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?

CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 8 / 10.


What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?

The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 14.31% in the next year.